Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Study
Nucleosides Nucleotides Nucleic Acids. 2023 Dec 20:1-21. doi: 10.1080/15257770.2023.2296021. Online ahead of print.ABSTRACTImatinib (IMA) and nilotinib are the first and second generations of BCR-ABL tyrosine kinase inhibitors, which widely applied in chronic myeloid leukemia (CML) treatment. Here we aimed to provide new targets for CML treatment by transcriptome analysis. Microarray data GSE19567 was downloaded and analyzed from Gene Expression Omnibus (GEO) to identify common genes, which are downregulated or upregulated in K562-imatinib and K562-nilotinib treated cells. The differentially expressed genes (DEGs) were ass...
Source: Nucleosides, Nucleotides and Nucleic Acids - December 20, 2023 Category: Biochemistry Authors: Yalda Hekmatshoar Yalda Rahbar Saadat Tulin Ozkan Sureyya Bozkurt Aynur Karadag Gurel Source Type: research
Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials
Tyrosine Kinase Inhibitors (TKIs) is revolutionizing the management of pediatric Chronic Myeloid Leukemia (CML), offering alternatives to Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). We conducted a comprehensive review of 16 Randomized Controlled Trials (RCTs) encompassing 887 pediatric CML patients treated with TKIs including Imatinib, Dasatinib, and Nilotinib. The median patient age ranged from 6.5 to 14 years, with a median white blood cell count of 234 x 10^9/uL, median hemoglobin level of 9.05 g/dL, and median platelet count of 431.5 x 10^9/µL. Imatinib seems to be predominant first line TKI, with the ...
Source: Frontiers in Oncology - December 20, 2023 Category: Cancer & Oncology Source Type: research
Novel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease
CONCLUSION: While their efficacy needs to be better evaluated through large-scale, multicenter, randomized clinical trials, these novel agents show potential and could provide a better alternative for SR-GVHD treatment in the future.PMID:38094101 | PMC:PMC10718798 | DOI:10.1155/2023/9949961 (Source: Advances in Hematology)
Source: Advances in Hematology - December 14, 2023 Category: Hematology Authors: Iuliia Kovalenko Tabinda Saleem Mitali Shah Sara Seyedroudbari Konstantin Golubykh Rimsha Ali Taaha Mirza Babray Laek Ahsan Wahab Asmi Chattaraj Ekaterina Proskuriakova Chandi Garg Rafiullah Khan Source Type: research
Resistance mutations in CML and how we approach them
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):469-475. doi: 10.1182/hematology.2023000447.ABSTRACTAmong the variety of resistance mechanisms that may underlie a non-optimal response to tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia patients, secondary point mutations in the BCR::ABL1 kinase domain (KD) represent the only actionable one. Each of the 5 ATP-competitive inhibitors (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) has a well-defined spectrum of resistance mutations. Growing clinical experience will soon allow to also elucidate the full spectrum of mutations conferring resi...
Source: Hematology ASH Education Program - December 9, 2023 Category: Hematology Authors: Simona Soverini Source Type: research
